MID Second Half Notes:


L53: HIV Treatment:
	- HIV notes:
		- viral load has set point
		- CD4 decline rate dependent on viral load set point
		- timeline:
			- primary: ~ 6 months
			- asymptomatic: 3-10 yrs
			- AIDS: ~ 7 years after infection
	- anti-retroviral treatment:
		- nucleoside reverse transcriptase inhibitors (NRTIs):
			- mechanism: prevent DNA elongation (missing 3' -OH)
			- types:
				- zidovudine: mother-child prevention
					- significant side effects: nausea, vomitting, headache, macrocytic anemia, peripheral neuropathy, lipodystrophy
				- abacavir: HLA B57:01 fatal hypersensitivity reaction
				- lamivudine: low resistance barrier
				- emtricitabine: low resistance barrier
				- tenofovir disproxil fumarate (TDF): rare proximal tubule damage, - bone density
				- tenofovir alafenamide (TAF): +LDL, +weight

		- non-nucleoside reverse transcriptase inhibitors (NNRTIs):
			- mechanism: prevent DNA synthesis enzyme
			- types:
				- first gen: low half-lives, low resistance barrier
					- efavirenz: neuropsych SEs, rare skin + hepatotoxicity
					- nevirapine: rare skin + hepatotoxicity
				- second gen: less SEs
					- etravirine: 2x daily, not used
					- rilpivirine: strong oral, injectable
					- doravirine

		- protease inhibitors (PIs):
			- powerful (1995)
			- given with "booster"
			- very high resistance barrier
			- CYP 450 3A4 inhibitor
			- SEs:
				- GI (bloating, nausea, etc)
				- lipodystrophy + dyslipedemia
				- older PI: risk of MI
			- types:
				- lopinavir
				- atazanavir
				- darunavir

		- integrase inhibitors (INSTIs):
			- rapid viral decay (2007)
			- SEs: very few, metabolic syndrome like
			- types:
				- 1st gen:
					- low resistance barrier
					- raltegravir: 2x daily
					- elvitegravir: needs "booster"
				- 2nd gen:
					- high resistance barrier
					- dolutegravir
					- bictegravir
					- cabotegravir: PO, IM

		- pharmacoenhancers ("booster"):
			- types:
				- ritonavir: low dose, early gen PI, GI discomfort
				- cobicistat: GI discomfort

		- entry inhibitors:
			- fusion inhibitors:
				- binds GP41 envelope glycoprotein blocking fusion
				- type: enfuvirtide (T20) injectable, rarely used
			- CCR5 antagonist:
				- blocks CD4+ chemokine co-receptor
				- type: maraviroc
				- use: CCR5 tropic virus

			- CD4 post-attachment inhibitor:
				- monoclonal Ab stops viral fusion
				- type: ibalizumab-uiyk IV
				- use: MDR HIV
			- attachment inhibitor:
				- binds gp120, blocks virus/CD4 coupling
				- type: fostemsavir -> temsavir
				- use: MDR HIV


		- combination therapy:
			- triple therapy:
				- 2 NRTIs + base
			- dual therapy:
				- 1 INSTI + 1 NRTI

L36-37 nematodes:
	- roundworms
	- intestinal, blood, larvae migrate through tissue

	- enterobias vermicularis:
		- pinworm
		- cycle: oral-fecal
		- pathogenesis
			- peri-anal itch
			- no eosinophilia
		- dx:
			- scotch tape/paddle test
		- tx: albendazole (retreat)

	- trichuris trichuria:
		- whipworm
		- cycle: oral-fecal
		- pathogenesis:
			- attach cecum/colon
		- sx:
			- rectal prolapse
			- systemic anemia
			- clubbing
			- bleeding
		- dx:
			- stool O&P
		- tx: albendazole

	- ascaris lumbricoides:
		- cycle:
		- pathogenesis:
			- lung migration -> loefflers syndrome
		- sx:
			- bowel obstruction in children
			- biliary invasion
			- pancreatitis
		- dx:
			- recover worm
			- stool O&P
		- tx: albendazole

	- necator americanus / ancylostoma duodenale:
		- hookworm
		- cycle:
		- pathogenesis:
			- penetrate skin -> lung migration
			- loefflers syndrome
		- sx:
			- iron deficient anemia
		- dx:
			- stool O&P
		- tx: albendazole

	- strongyloides:
		- cycle
		- pathogenesis:
			- penetration of skin
		- sx:
			- acute:
			- chronic:
		- dx:
			- stool O&P (acute)
			- serology (chronic)
			- sputum O&P (hyperinfection)
		- tx: ivermectin


	- larva migrans
		- cutaneous
		- visceral
	- 


L41-42 flukes:
	- flat, anterior/ventral sucker
	- host: snails
	- schistosomiasis
		- pathogenesis:
			- live in blood vessels
			- penetrate skin
		- cycle:
			- water -> penetrate skin -> lungs -> heart -> liver -> bowel/bladder
		- acute:
		- acute (katayama):
			- immediate: pruritic, papular rash "swimmers itch"
			- 4-8 weeks post infection
			- sx:
				- systemic
				- urticaria
				- eosinophila
				- hyperglobulinemia
				- lymphadenopathy
				- heptaosplenomegaly
		- chronic:
			- egg granuloma -> fibrosis
			- sx:
				- colonic polyposis: microabscesses
				- diarrhea (pediatric)
				- LLQ pain
			- liver:
				- granulomas -> periportal fibrosis
				- block sinusoids -> portal htn
				- sx:
					- portal htn
					- varices / bleeding
					- splenomegaly + hyperspenism
					- anemia
					- reduced immune responses
			- urinary:
				- sx:
					- 10-12 weeks after infection
					- hematuria / dysuria
					- late:
						- bladder calcifications
						- proteinuria
						- CKD
						- ureter obstruction

			- dx:
				- biopsy
				- stool O&P
				- serology: persistent

		- tx:
			- praziquantel, only for adult worms, must retreat
	
	- liver fluke:
		- fasciola hepatica
		- 1.5 cm fluke
		- watercress
		- cycle: stool -> water -> snails -> watercress + animals -> intestines -> glissons capsule -> liver
		- forms:
			- acute hepatic:
				- 6-12 post ingestion
				- sx:
					- eosinophilia
					- abdominal pain (RUQ)
					- fever, systemic
					- anorexia
					- hepatomegaly
				- dx:
					- large on CT scan
			- chronic:
				- lumen of bile duct
				- acute symptoms resolve
				- sx:
					- sometimes asymptomatic
					- biliary obstruction / cholecystitis
					- ascending cholangitis
					- jaundice
					- RUQ pain
					- gall bladder lithiasis
				- dx: US
		- tx: triclabendazole

	- paragonimiasis:
		- endemic hemoptysis
		- crustacea / crabs
		- cycle:
			- metacerariae ingested -> intestines -> peritoneum -> lungs
		- pathogenesis:
			- granulomas -> fibrosis + bronchiectasis
			- bronchiolar fistula
		- sx:
			- productive cough
			- blood sputum, hemoptysis
			- pleuritic chest pain
			- fever + pleural effusion
			- eosinophilia
		- dx: 
			- xray: nodules, patchy infiltrates, calcifications
			- eggs in sputum
			- serology 
			- biopsy
		- tx: praziquantel


L46 cestodes:
	- flat worms, sexual segments
		- scolex (head)
		- proglottids (sections)
	- tx: praziquantel

	- diphyllobothrium latum
		- source: fish
		- size: 3-12 meter
		- dark rosette
		- sx:
			- few, fatigue, pernicious anemia, HA
			- 1/5 abdominal pain + discomfort
			- B12 deficiency

	- cysticercosis:
		- taenia saginata:
			- beef
			- intact proglottid
			- sx:
				- abdominal pain
				- no eosinophilia
		- taenia solium:
			- pork
			- sx:
				- asymptomatic: usually
				- epigastric pain + umbilical pain
				- nausea, hunger, anorexia
				- eosinophilia
			- neurocysticercosis:
				- vesicular -> colloidal -> granular -> calcified
				- dx:
					- CT/MRI
					- serology (not sensitive for single cyst or calcified lesion)
				- tx:
					- 1-2 lesions: albendazole
					- >2 lesions: albendazole + praziquantel
					- steroids + antiepileptics prophylaxis PRN
					- calcified lesions: antiepileptics
					- subarachnoid: albendazole + praziquantel
					- intraventricular: ball valve -> removal

	- echinococcus:
		- host: dog
		- intermediate host: humans + animals
		- pathogenesis:
			- invade from GI
			- hydatid cysts with endocyst
		- sx:
			- liver: RUQ
			- lungs: hemoptysis, cough, dyspnea
		- dx:
			- imaging
			- serology: w. blot spec > ELISA
		- tx:
			- adjunctive albendazole
			- surgical fields:
				- soak scolicidal agents
				- spillage -> praziquantel
			- CE 1: aspirate
			- CE 2: surgery
			- CE 3: surgery
			- CE 4/5: inactive, watch + wait (10 years)

L51-52: protozoa
	- amoeba:
		- nonflagellate protozoa
		- types:
			- invasive: entamoeba hystolytica
			- non-invasive: e. dispar, moshkovskii
		- cycle:
			- fecal cysts ingested
			- gastric acid releases trophozoites
			- invade colon -> liver
		- pathogenesis:
			- glycosidases: lyse PMNs on contact
			- necrotic foci ulcers
			- vasculitis + thrombosis
		- tx:
			- abscess: metronidazole
			- luminicidal:
				- iodoquinol
				- paromomycin
				- diloxanide furoate
		- dx:
			- stool O&P
			- biofire (PCR)
			- stool Ag

		- syndromes:
			- asymptomatic
			- mucosal:
				- bloody diarrhea
				- acute rectocolitis
					- onset: 1-3 week
					- sx: 
						- abdominal pain + tenderness
						- bloody stools + tenesmus
						- fever (30%)
				- chronic nondysenteric colitis:
					- frequent stools
					- abdominal cramping
					- weight loss, anorexia, nausea
			- liver abscess:
				- leukocytosis
				- fever, RUQ pain
				- no eosinophilia
				- elvated ESR
				- dx: serology/aspiration
			- transmural:
				- fulminant colitis + perforation
				- toxic megacolon
			- ulcerative postdysenteric colitis (rare)

	- trichomonas vaginalis:
		- STI
		- sx:
			- discharge, pruritis
			- painful coitus
			- vaginal erythema
		- tx: metronidazole

	- toxoplasma gondii:
		- cycle:
			- cat feces -> meat or ingestion
	 	- pathogenesis:
	 		- invade cells
	 	- acute disease:
	 		- painless lymphadenopathy (single cervical)
	 		- fever, headache, malaise, myalgia
	 	- affected fetus:
	 		- retinal scars
	 		- psychmotor impairment
	 		- ocular disease:
	 			- pain, photophobia, blurred vision
	 			- hazy/yellow patches on eye exam
	 	- AIDs (<100):
	 		- multifocal necrotizing encephalitis

	 	- tx:
	 		- sulfadiazine-pyrimethamine:
	 			- folate pathway inhibitor
	 		- alt: bactrim, clindamycin
	 	- dx:
	 		- serology, 4x rise in IgG
	 		- PCR/histology



L54 kinetoplastids:
	- chagas disease:
		- trypanosoma cruzi
		- vector: triatomine
		- tx:
			- < 50 yo: treat
			- advanced disease: no
		- dx:
			- giemsa smear
			- PCR (CDC double check): persistent antibodies
			- culture
		- cycle:
			- blood -> vector -> blood -> gut -> feces
			- feces/blood -> muscle -> muscle rupture
			- transmission: vector / blood tx/nursing/transplant
		- pathogenesis:
			- trypomastigotes invade SMC/cardiomyocytes
			- cause fibrosis + atrophy
			- reactivation in tx patients
		- sx:
			- acute:
				- often children
				- romana's sign (eyelid edema, weeks)
				- chagoma
				- fever, systemic sx
				- heptaosplenomegaly
				- atypical lymphocytosis
				- rare:
					- arrhythmias
					- acute meningoencephalitis
					- myocarditis
			- chronic:
				- ~70% asymptomatic
				- ~30%: cardiomyopathy:
					- RBBB, LAFB
					- arrhythmias: AFib/Flutter, AV blocks, VT
					- cardiomegaly, hypertrophy + dilatation
					- apical aneurysm (30%)
						- intracardiac thromi
				- GI disease:
					- intramural neuron degeneration
					- sever constipation, fecaloma (megacolon)


	- leishmaniasis:
		- vector: sandfly
		- dx:
			- biopsy
			- PCR
			- giemsa smear
			- K39 antigen
		- visceral (kala-azar):
			- insidious onset (weeks to mos)
			- sx:
				- fever, weight loss
				- anorexia
				- massive splenomegaly
				- pancytopenia (anemia, leukopenia, etc)
				- dark pigmentation
			- tx: amphotericin B

		- cutaneous (old world):
			- non-healing sores
			- tx: amphotericin B
		- mucosal (new world / espundia):
			- brazilienesis
			- sx:
				- nodular lesions: nasal septum, nasopharyngeal
				- horrifying
			- onset: days to years
			- tx: topical



L55 COVID-19:
	- structure:
		- lipid bilayer
		- hemagglutinin (HE)
		- spike protein (S)
		- membrane protein (M)
		- envelope glycoprotein (E)
		- RNA based
	- pathogenesis:
		- binds ACE2 -> TMPRSS2 fusion
		- viral shedding peaks 1 day after symptom onset
		- starts 2-3 days before symptoms

	- epidimiology:
		- 80% transmission from 10% of infected
		- 80% cases: mild, URI
		- 20% cases: ARDS, ALI, cytokine storm
	- risks:
		- age (highest)
		- auto IFN antibodies (second highest)
	- tx:
		- nirmatrelvir (paxlovid):
			- inhibits processing of RNA pol protein
			- given with booster (ritonavir)
			- 90% reduction in severe disease
		- remdesivir:
			- mRNA synthesis inhibitor
			- Adenosine nucleoside analog
			- 87% reduction in progression if given < 5 days
		- molnupiravir:
			- mRNA synthesis inhibitor
			- cytidine nucleoside analog
			- 30% reduction in progression if given < 5 days
		- monoclonals:
			- bind spike -> block ACE2 binding
			- types:
				- tixagevimab
				- cilgavimab
				- bebtilovimab (for omicron)










































